ClinicalTrials.gg
RecruitingNCT06228352ABRICOUpdated Jun 24, 2026

Role of Bile Acids and Microbiota in Clostridioides Difficile Infection in Ulcerative Colitis

An observational study in Ulcerative Colitis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know · 2 judgments

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
80
Ages
Up to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, 1 of them phase 3. Colitis, Ulcerative · Assistance Publique - Hôpitaux de Paris.

Started
2026
with 2 others
Observational
4 of 10
3 open now
Registered
7th of 10
by date

Among the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, this one is one of 3 that started in 2026, is one of 4 observational ones, and was the 7th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

6 of the 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: Up to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colitis, Ulcerative by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Ulcerative Colitis (UC) is a chronic Inflammatory Bowel Disease characterized by chronic inflammation of the colon. Composition of gut microbiota of UC patients is abnormal (dysbiosis).

Ulcerative Colitis patients have an increased risk of Clostridioides difficile infection (CDI) and CDI complications (colectomy, death, recurrence). The reason for this increased risk in IBD patients is not fully understood. The decrease in the proportion of secondary bile acids, induced by microbiota dysbiosis in patients with UC could favor C. difficile infection.

The main objective of the study is to describe the composition of bile acids (primary and secondary) in children followed for UC during relapse with or without CDI and to compare it to children with UC in remission and healthy controls. The composition of fecal microbiota will be also describe to correlate dysbiosis and bile acid abnormalities. And finally some fecal biomarkers will be study : short chain fatty acids, metabolic pathway of Tryptophan, and fecal Calprotectin.

Read the detailed description

Ulcerative Colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by chronic inflammation of the colon. Clinical symptoms include bloody diarrhea associated with abdominal pain, fecal incontinence, urgency, and tenesmus. Approximately 15-20% of patients develop UC during childhood or adolescence, with a sustained worldwide rise of the incidence of IBD, particularly pediatric forms. While there are many similarities between adult- and childhood-onset UC, pediatric-onset UC appears to be more severe and extensive with more rapid spread of the disease leading to high morbidity, more severe acute flares and more frequent use of intravenous corticosteroids. To date, there is no medical treatment that can cure the disease but only treatments that shorten the duration of relapses or prevent them.

An imbalance in the composition of the intestinal microbiota named "dysbiosis" has been demonstrated in IBD. This dysbiosis is characterized by a strong instability of the microbiota over time, and a reduction of diversity and particularly a reduction in bacteria belonging to the Firmicutes and Bacteroidetes phyla with an increase in Proteobacteria and Actinobacteria. More recently, a UC-specific dysbiosis has been described including a decrease in butyrate-producing bacteria, in particular Faecalibacterium prausnitzii, and Roseburia hominis.

It has also been shown that if adult patients with UC in flare-up and remission have similar total fecal bile acids, they have a lower proportion of fecal secondary acids compared to healthy control subjects.

Patients with UC have an increased risk of Clostridioides difficile infection (CDI) and complications from the CDI (coletomy, deaths) as well as a higher risk of CDI recurrences. Clostridioides difficile is a strict anaerobic bacteria, which represents the main cause of post-antibiotic diarrhea.

The hypothesis of the project is that gut microbiota dysbiosis in patients with UC alters the bile acid profile and metabolite profile and could promote C difficile infection in these patients without any other risk factors such as antibiotics. To confirm this hypothesis, the investigating team proposes to study the microbiota, bile acid profiles and microbial metabolites in the stools of 40 pediatric-onset UC patients with a flare-up of their disease with (n=20) or without (n=20) a concomitant CDI and to compare them to healthy children (n=20) and UC children with clinical remission (n=20). Bile acids will be determined by high performance liquid chromatography coupled with tandem mass spectrometry detection, the short chain fatty acids and tryptophan derivatives derived from TRP and AGCC will be determined by GC-MS or LC-MS and the microbiota by the MiSeq technique.

The investigating team hopes to identify bile acid profiles predisposing for CDI and to correlate them with microbiota abnormalities. This will allow to better understand the factors associated with CDI but also to identify biomarkers of infection and maybe protective bacterial strains. In the long term, the investigating team hopes to find new therapeutic perspectives by providing bacteria of interest to transform bile acids and to protect against Clostridioides difficile.

03

Conditions studied

  • Ulcerative Colitis

Keywords

  • Ulcerative colitis
  • Clostridioides difficile infection
  • Intestinal dysbiosis
  • Bile acid profiles
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients consulting or hospitalized in the Gastroenterology department of Necker-Enfants Malades Hospital, with ulcerative colitis (UC) in flare-up with and without Clostridioides difficile infection (CDI), patients UC in remission and healthy controls.

Eligibility criteria

For everyone :

Inclusion Criteria:

  • Pediatric patients (\<18 years) consultant or hospitalized in the Gastroenterology department of Necker-Enfants Malades Hospital.
  • Information and consent of parents and the patient

Exclusion Criteria:

  • Patient who received antibiotic or antifungal treatment in the 4 weeks prior to inclusion.
  • Patients colonized by C. difficile.
  • Pregnant or breastfeeding young girl.
  • Refusal of the protocol by parents or patient.

For group 1: Patients with active UC

Inclusion criteria:

  • Patient with UC, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria.
  • UC in flare defined by a PUCAI score of between 35 and 65.

Non-inclusion criteria:

  • Patient with IBD unclassified or Crohn's disease.
  • Patient with isolated proctitis (\<5 cm).
  • Colectomized patients.
  • Patients with sclerosing cholangitis associated with their UC or liver disease.

Group 2: Patients in UC remission

Inclusion criteria:

  • Patient with UC, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria.
  • UC in remission defined by a PUCAI score \<10.

Non-inclusion criteria:

  • Patient with IBD unclassified or Crohn's disease.
  • Patient with isolated proctitis (\<5 cm).
  • Colectomized patients.
  • Patients with sclerosing cholangitis associated with their UC or liver disease.

Group 3: Healthy control subjects

Inclusion criteria:

- Patients hospitalized for an endoscopic assessment to control for abdominal pain, gastroesophageal reflux or polyposis.

Non-inclusion criteria:

  • Patient with chronic liver disease.
  • Patient with chronic digestive disease (celiac disease, IBD, chronic chronic).
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Ulcerative colitis flare-up

    Patient with ulcerative colitis, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months, presenting with a flare of UC defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) score between 35 and 65.

    Other: Feces collection

  • Ulcerative colitis remission

    Patient with ulcerative colitis, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months and in clinical remission defined by a Pediatric Ulcerative Colitis Activity Index (PUCAI) score under 10.

    Other: Feces collection

  • Controls

    Paediatric patients (\<18 years) without chronic liver disease or chronic digestive disease (celiac disease, inflammatory bowel disease, chronic diarrhea) and hospitalized for an endoscopic examination to investigate abdominal pain, gastroesophageal reflux or polyposis.

    Other: Feces collection

Interventions

  • OtherFeces collection

    A single stool sample will be taken (a specific kit will be given to the patient for this) during a consultation for follow-up or hospitalization. Stool samples will be used to study the composition of the intestinal microbiota and to measure faecal biomarkers.

06

What researchers measure

Primary outcomes

  1. Composition of bile acids

    Description of the composition of primary and secondary bile acids. Fecal bile acids will be assayed by high performance liquid chromatography coupled with detection by tandem mass spectrometry and the quantification of each bile acid will be expressed as a percentage of total bile acids. The bile acid profile of the patients will be compared between the 3 groups: patients followed for ulcerative colitis (UC) in flare with or without a concomitant C difficile infection, patients with UC in clinical remission and healthy subjects without UC.

    Time frame: Day 0

Secondary outcomes

  1. Faecal microbiota

    The composition of the patients' faecal microbiota will be measured by targeted metagenomics (high-throughput sequencing of DNA coding for 16S RNA targeting the V3-V4 region). The analysis of the diversity of the microbiota will be carried out by calculating the Shannon index. This index will be compared between the groups with and without CDI.

    Time frame: Day 0

  2. Short-chain fatty acids

    Analysis of fecal biomarkers. Short-chain fatty acids (SCFAs; acetate, propionate, butyrate and branched short-chain fatty acids) and metabolites of the tryptophan pathway will be determined by gas or liquid chromatography methods, coupled with mass spectrometric detection. The results will be compared between the 3 groups.

    Time frame: Day 0

  3. Metabolic pathway of tryptophan

    Analysis of fecal biomarkers. Metabolites of tryptophan pathway will be determined by gas or liquid chromatography methods, coupled with mass spectrometric detection The results will be compared between the 3 groups.

    Time frame: Day 0

  4. Fecal calprotectin

    Analysis of fecal biomarkers. Fecal calprotectin assay will be done by chemiluminescence assay. The results will be compared between the 3 groups.

    Time frame: Day 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2029, 36 months after the start.

Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 36 months is below that.

Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2024
First posted
Jan 29, 2024
StartActual
Jun 9, 2026
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2029
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06228352
Collaborators
URC-CIC Paris Descartes Necker Cochin
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Jun 9, 2026
Primary completion
Jun 2029 (estimated)
Completion
Jun 2029 (estimated)
Last update
Jun 24, 2026

Study contacts

Bénédicte Pigneur, MD
Contact
benedicte.pigneur@aphp.fr
1 44 49 25 16 ext. +33
Hélène Morel
Contact
helene.morel@aphp.fr
1 71 19 63 46 ext. +33
Bénédicte Pigneur, MD
principal investigator · Assistance Publique - Hôpitaux de Paris
Frédéric Barbut, PhD
study director · Institut National de la Santé Et de la Recherche Médicale, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion